Starting from the structure of DuP-753 and a 3-dimensional model of the pentapeptide Tyr-Ile-His-Pro-Ile, a series of new and highly potent antagonists has been designed where the imidazole moiety of the Du Pont compound has been-replaced by an N-acylated aminoacid residue. VALSARTAN (Ex. 4e, CGP48933, (S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl-)biphenyl-4-yl]methyl}-valine), has been selected for clinical investigation.
引用
收藏
页码:29 / 34
页数:6
相关论文
共 17 条
[1]
BUHLMAYER P, 1992, CURR OPIN THER PAT, V2, P1693